Literature DB >> 9184360

Non-gyrA-mediated ciprofloxacin resistance in laboratory mutants of Streptococcus pneumoniae.

L J Piddock1, Y F Jin, M J Everett.   

Abstract

Two strains of Streptococcus pneumoniae, M4 (NCTC 7465, type strain) and M5 (clinical isolate), and their respective ciprofloxacin-resistant mutants, M4/C1, M5/C1 and M5/C3, were evaluated. All mutants were stable after one year's storage and all grew more slowly in Brain Heart Infusion broth than the parent. The MICs of ciprofloxacin, sparfloxacin and tosufloxacin were increased for the mutants of M4, whereas the mutants of M5 were less susceptible to ciprofloxacin only. The optimal bactericidal concentration (OBC) of each quinolone for all the strains was approximately ten-fold greater than the MIC. The OBCs for the mutants were increased for ciprofloxacin, but not for the other two quinolones. The DNA synthesis IC50 values of all quinolones correlated well with the MIC of each drug. All quinolones accumulated rapidly within all five strains; 10 mM magnesium chloride decreased the concentration of quinolone accumulated, but carbonyl cyanide m-chlorophenyl hydrazone had no effect. Mutant strains M4/C1, M5/C1 and M5/C3 accumulated less quinolone than their respective parent strains. DNA sequencing of those regions of gyrA and gyrB corresponding to the quinolone resistance-determining region in other bacteria did not reveal any differences between the parent and mutant strains.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184360     DOI: 10.1093/jac/39.5.609

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Global transcriptome analysis of the responses of a fluoroquinolone-resistant Streptococcus pneumoniae mutant and its parent to ciprofloxacin.

Authors:  Estelle Marrer; A Tatsuo Satoh; Margaret M Johnson; Laura J V Piddock; Malcolm G P Page
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae.

Authors:  Laura J V Piddock; Maggie M Johnson; S Simjee; L Pumbwe
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

3.  Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae.

Authors:  Laura J V Piddock; M M Johnson
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 4.  Efflux-mediated drug resistance in bacteria.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Primary targets of fluoroquinolones in Streptococcus pneumoniae.

Authors:  H Fukuda; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

6.  Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.

Authors:  L J Piddock; M Johnson; V Ricci; S L Hill
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.